• Home
  • Search Results

Search Results

448 studies match your search
Open

Rehabilitation outcomes study

Have you been diagnosed with cancer. If so, you may be able to take part in a research study looking to improve cancer care for patients whose treatment outcomes have led to challenges in their quality of life.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 19 more)
Open

Basal-like PDAC treated with Gemcitabine, Erlotinib and nab-paclitaxel (PANGEA).

Are you a patient with advanced basal-like pancreatic adenocarcinoma? If so this could the a Trial for you to as this is a Phase I/II trial is to evaluate the safety, efficacy and tolerability of low-dose EGFR inhibitors in combination with bi-weekly gemcitabine/nab-paclitaxel (GnP) in subjects with basal tumors

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Pancreatic)
Open

First in Human Study of IMGN151 in adut patients with Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers.

Do you have Recurrent endometrial cancer,Recurrent, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer that has progressed during or after standard treatments? If so, you may be able to take part in a research study looking at the safety of giving a treatment of test drug IMGN151-1001 to patients with these types of cancer

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Uterine (endometrial), Ovarian)
Open

Venetoclax, MLN9708 and Dexamethasone for Relapsed or Refractory Light Chain Amyloidosis

Have you been diagnosed with relapsed or refractory light chain amyloidosis? If so, you may be able to take part in a research study looking at the safety and tolerability of giving Venetoclax, MLN9708 (ixazomib citrate) and Dexamethasone to patients with relapsed or refractory light chain amyloidosis.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Other Cancers)
Open

A PHASE 1/2A, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY, AND PHARMACOKINETICS OF REGN10597 (ANTI PD-1-IL2RA-IL2 FUSION PROTEIN) IN PATIENTS WITH ADVANCED SOLID ORGAN MALIGNANCIES

Do you have kidney or bladder cancer. You may be able to participate in a research study to find out if the investigational drug REGN10597 is safe, tolerable, and effective in treating kidney and bladder cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Kidney)
Open

Bladder Cancer Study

Do you have bladder cancer and have had your bladder removed? If so, you may be able to take part in a research study to determine if patients need additional treatment called immunotherapy to prevent cancer from coming back.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder)
Open

AIRPanc - Ph2 Randomized Study Evaluating Patients with advanced Pancreatic Ductal Adenocarcinoma

Have you been diagnosed with pancreatic adenocarcinoma? If so, you may be a good fit to help us learn if combination treatment with specific drugs may stimulate the body's immune system against cancer cells.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Pancreatic)
Open

MODERN

Do you have bladder cancer that has spread to nearby tissue or other parts of the body? You may be able to participate in a research study to find out if the investigational drug disitamab vedotin alone or with pembrolizumab works to treat bladder cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder)
Open

Lung Cancer Treatment Study

Do you have Stage III or Stage IV Non-Small Cell Lung Cancer? Do you have a KRAS G12C mutation or are you interested in testing for this? If so, you may be able to participate in a study to see if adding a new medicine is more effective at controlling your cancer than the usual treatments.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Lung)
Open

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Have you been diagnosed with Multiple Myeloma? Have you received idecabtagene vicleucel (ide-cel (Abecma)) CAR-T treatment? If so, you may be able to take part in a research study looking at for how long a new drug called iberdomide will keep Multiple Myeloma under control (in remission).

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Multiple Myeloma)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research